Company Profile
Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals.
Its operations are structured into three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer.
The company develops TLX250, an rADC for treating advanced metastatic kidney cancer. Its portfolio also includes TLX101, a systemic therapy for the treatment of glioblastoma, TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning, and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology.
Its portfolio also includes TLX252 for the treatment of patients with advanced metastatic kidney cancer, TLX400, a bladder fibroblast activation protein for treating various tumors, TLX102, a large amino acid transporter-targeting small molecule-based alpha therapy candidate for the treatment of glioblastoma and multiple myeloma, TLX300 for treating soft tissue sarcoma, and TLX090, a bone-seeking agent for bone metastases and pain palliation.
Additionally, it is developing BiPASS, which is in Phase 3 clinical trial for prostate cancer diagnosis. Its portfolio also includes AlFluor, a novel PET radiochemistry solution, TLX250-Px, a PET diagnostic imaging agent, and TLX101-Px, a radiolabeled amino acid PET agent. It operates globally. The company has strategic collaboration with University Hospital Essen. Founded in 2015, the company is headquartered in North Melbourne, Australia.